These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 32562207)

  • 1. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
    Gisbert JP; Chaparro M
    Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2023 Jun; 17(6):995-1009. PubMed ID: 36652274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
    Mitrova K; Pipek B; Bortlik M; Bouchner L; Brezina J; Douda T; Drasar T; Klvana P; Kohout P; Leksa V; Minarikova P; Novotny A; Svoboda P; Skorpik J; Ulbrych J; Veinfurt M; Zborilova B; Lukas M; Duricova D;
    J Crohns Colitis; 2022 Dec; 16(12):1808-1815. PubMed ID: 35708729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
    Chang S; Hudesman D
    Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
    Picardo S; Seow CH
    Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for the treatment of IBD during conception, pregnancy, and lactation.
    Pugliese D; Privitera G; Gisbert JP; Chaparro M
    Dig Liver Dis; 2024 Feb; 56(2):235-241. PubMed ID: 37718225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
    Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
    Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis.
    Laube R; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2021 Mar; 20(3):275-292. PubMed ID: 33412078
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing Risks with Biologics.
    Click B; Regueiro M
    Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.
    Irving PM; Hur P; Gautam R; Guo X; Vermeire S
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1026-1040. PubMed ID: 39213145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
    Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD
    Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
    Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
    Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Emerging Therapies: What Are Promising in the Near Future?].
    Seo GS; Lee SH
    Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis.
    Novello M; Stocchi L; Holubar S; Shawki S; Lipman J; Gorgun E; Hull T; Steele SR
    Int J Colorectal Dis; 2019 Mar; 34(3):451-457. PubMed ID: 30535559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.